U.S. Retinal Disease Diagnostic Devices Market 2025: $1.75B

Market Outlook

By 2035, the U.S. Retinal Disease Diagnostic Devices Market is estimated to reach approximately USD 4.62 billion, expanding at a CAGR of 10.20% during the forecast period 2026–2035. The market is estimated at USD 1.75 billion in 2025, following historical expansion from approximately USD 1.16 billion in 2021, USD 1.29 billion in 2022, USD 1.43 billion in 2023, and USD 1.59 billion in 2024. Values in this report are expressed in USD billions.

The market sizing represents an analyst-built U.S. estimate based on retinal imaging system installations, equipment replacement cycles, average selling prices, multimodal imaging adoption, retinal screening deployments, software and analytics attachment, home-monitoring development, diagnostic procedure demand, and procurement patterns across ophthalmology and retina care. Therapeutic retinal lasers, vitrectomy equipment, pharmaceuticals, predominantly anterior-segment diagnostic equipment, and general vision-correction products are excluded.

The U.S. retinal disease diagnostic devices industry is entering a higher-value technology cycle in which retinal diagnosis is shifting from conventional examination and single-modality photography toward quantitative, multimodal and increasingly decentralized imaging. Optical coherence tomography, swept-source OCT, OCT angiography, ultra-widefield retinal imaging, fundus autofluorescence, scanning laser ophthalmoscopy, artificial intelligence-assisted image analysis, portable retinal cameras and emerging home OCT systems are progressively reshaping how retinal disease is detected, characterized and monitored.

The underlying clinical need is substantial. Approximately 19.8 million Americans aged 40 years and older were estimated to have age-related macular degeneration in 2019, including approximately 1.49 million people with vision-threatening disease. In 2021, approximately 9.6 million people in the United States were estimated to have diabetic retinopathy, including roughly 1.84 million with vision-threatening diabetic retinopathy. More recently, approximately 40.1 million Americans were estimated to have diagnosed or undiagnosed diabetes in 2023, materially expanding the population requiring longitudinal retinal screening and risk assessment.

Demographic change adds another structural demand layer. The U.S. population aged 65 and older reached approximately 61.2 million in 2024, equivalent to around 18% of the population. Because prevalence of AMD, diabetic eye complications and multiple vitreoretinal disorders rises sharply with age, expansion of the older population supports increasing diagnostic encounters, OCT examinations, fundus imaging, treatment-response monitoring and retina-specialist referrals.

The economic direction of the market is also changing. Retina specialists and health systems increasingly evaluate imaging equipment not only on image resolution but on patient throughput, repeatability, automated acquisition, multimodal integration, longitudinal comparison, technician dependence, cloud connectivity and ability to support treatment decisions. Large practices may prefer premium platforms capable of supporting thousands of follow-up examinations, while primary care, endocrinology and community screening environments favor compact retinal cameras and automated AI workflows.

Between 2026 and 2035, value creation is expected to migrate increasingly toward platforms that combine imaging hardware, automated acquisition, clinical analytics, data management and remote monitoring. A high-performance retinal diagnostic device will no longer be evaluated simply as a camera or scanner; its economic value will increasingly depend on how effectively it identifies actionable disease, supports referral decisions, reduces unnecessary specialist visits, improves imaging throughput and enables clinicians to measure disease progression over time.

Introduction

According to the U.S. Retinal Disease Diagnostic Devices Market Report, retinal diagnostics occupy a strategically important position within U.S. ophthalmology because many vision-threatening retinal diseases require structural or vascular visualization that cannot be adequately characterized through visual acuity testing alone. Modern retina care relies heavily on imaging to identify macular fluid, retinal thickening, geographic atrophy, neovascular activity, vascular abnormalities, retinal tears, hemorrhage, peripheral pathology and subtle structural change.

The market includes capital equipment, portable and handheld devices, software-enabled imaging platforms and emerging home diagnostic systems. Core technologies include spectral-domain optical coherence tomography, swept-source OCT, OCT angiography, conventional and non-mydriatic fundus cameras, ultra-widefield imaging systems, confocal scanning laser ophthalmoscopy, fundus autofluorescence, fluorescein and indocyanine-green angiography-enabled platforms, ophthalmic ultrasound and AI-enabled retinal image-analysis systems.

This breadth gives the market an attractive combination of recurring equipment replacement and new technology penetration. Established OCT and fundus imaging equipment generates a stable installed-base opportunity, while premium multimodal platforms, swept-source systems, automated screening solutions and home monitoring are expanding the accessible value pool.

The transition is particularly visible in OCT. Contemporary high-performance systems can acquire tens of thousands of A-scans per second, produce cross-sectional retinal maps, measure macular thickness and visualize retinal microstructure at a level not possible through conventional photography. ZEISS CIRRUS 6000, for example, operates at 100,000 scans per second and supports OCT angiography and wider-field imaging, while Topcon’s Triton platform combines swept-source OCT with multimodal retinal imaging.

The clinical model is moving from detecting obvious retinal abnormalities to quantifying disease longitudinally. For patients receiving treatment for neovascular AMD or diabetic macular edema, image comparability and segmentation accuracy can influence decisions concerning treatment intervals. For geographic atrophy and inherited retinal disease, high-quality multimodal documentation is increasingly valuable for measuring disease evolution. For diabetic retinopathy, automated image analysis creates the possibility of moving initial screening away from specialist clinics and closer to the patient’s routine diabetes-care environment.

FDA regulation is evolving alongside these changes. Retinal diagnostic AI is now represented by a dedicated Class II retinal diagnostic software category, and the regulatory framework recognizes software designed to analyze fundus images and identify referable diabetic retinopathy. Home ophthalmic OCT has also become a defined Class II category, establishing an important regulatory pathway for self-imaging systems used between scheduled physician assessments.

For manufacturers, investors and health systems, the central market question is therefore not simply how many OCT scanners or retinal cameras will be sold. The more important issue is how diagnostic workflows will redistribute between retina practices, comprehensive ophthalmology, optometry, diabetes clinics, primary care, teleophthalmology and the patient’s home.

Key Market Drivers: What Is Fueling the U.S. Retinal Disease Diagnostic Devices Market?

The most powerful structural driver is the scale of retinal disease burden. AMD represents one of the largest age-related retinal disease populations in the United States, while diabetic retinopathy creates a recurring screening requirement across a very large diabetes population. The approximately 19.8 million Americans aged 40 and older estimated to have AMD and the 9.6 million people estimated to have diabetic retinopathy represent overlapping but distinct demand pools for retinal photography, OCT, OCT angiography, autofluorescence and specialist imaging.

Diabetes is especially important from a market-development perspective because screening is repeatable, protocol-driven and potentially scalable outside specialist settings. U.S. diabetes prevalence reached an estimated 40.1 million people in 2023, while millions remain undiagnosed. This creates a large potential examination pool for retinal screening technologies that can be placed within endocrinology offices, primary care systems, community clinics and integrated delivery networks rather than requiring every patient to first access a retina specialist.

A second major driver is the growing clinical dependence on OCT. OCT has moved from a premium ophthalmic diagnostic technology to a central tool in medical retina practice. Imaging is frequently repeated because retinal diseases can change between visits and because treatment decisions often depend on subtle changes in retinal anatomy. The resulting economic opportunity is stronger than in equipment categories where a diagnostic procedure is performed only once.

OCT also creates an installed-base replacement cycle. Retina practices with older spectral-domain platforms increasingly evaluate newer systems offering faster scanning, larger scan areas, enhanced image averaging, OCT angiography, improved segmentation, automated follow-up registration and more integrated data management. Procurement therefore reflects both expansion of retinal diagnostic capacity and replacement of earlier-generation devices.

A third driver is the shift toward multimodal imaging. Retinal disease is often better characterized when structural OCT is interpreted alongside color photography, autofluorescence, angiography or ultra-widefield images. Manufacturers are responding by consolidating modalities within fewer systems. Heidelberg Engineering’s SPECTRALIS platform, for example, combines confocal scanning laser ophthalmoscopy with spectral-domain OCT and can incorporate multiple posterior-segment imaging modes. Optos Silverstone integrates ultra-widefield retinal imaging with image-guided swept-source OCT, supporting imaging from the posterior pole into the retinal periphery.

This consolidation matters economically. U.S. retina practices operate under significant technician, examination-room and physician-time constraints. A system that reduces patient movement between devices, improves image registration and creates a unified longitudinal record can potentially generate greater operational value than multiple independent diagnostic platforms.

A fourth growth driver is AI-enabled diabetic retinopathy screening. The FDA’s retinal diagnostic software category now includes multiple companies and devices. Digital Diagnostics, Eyenuk, AEYE Health and iHealthScreen have regulatory activity in diabetic retinopathy detection, demonstrating that autonomous or automated retinal analysis has moved beyond experimental development into an established U.S. regulatory category.

AI changes the market because it can separate image acquisition from specialist interpretation in selected screening workflows. A trained staff member may acquire retinal images while software performs automated analysis and generates a screening result. This potentially expands retinal diagnostics into non-ophthalmic environments and creates a new purchasing constituency that evaluates simplicity, imageability, workflow integration and referral generation rather than advanced retinal subspecialty functionality.

A fifth driver is the rising demand for earlier disease identification. Many retinal disorders can progress before patients experience major symptoms. Earlier detection is therefore clinically important, particularly in diabetic retinopathy, AMD and peripheral retinal pathology. Widefield imaging, non-mydriatic photography and automated screening can lower operational barriers to capturing retinal images in broader patient populations.

A sixth driver is aging. The U.S. 65-plus population rose to approximately 61.2 million in 2024, and the share of older Americans continues to increase. AMD prevalence rises particularly sharply with age; CDC modeling indicates prevalence increased from approximately 2% among people aged 40–44 to more than 46% among those aged 85 and older. This relationship makes demographic aging highly relevant to future retinal diagnostic utilization.

A seventh driver is the expansion of retinal treatment monitoring. Advances in intravitreal therapy have increased the importance of repeated imaging because physicians need objective anatomical information to determine disease activity and response. The diagnostic device market therefore benefits indirectly from therapeutic innovation. More patients being actively managed for AMD, diabetic macular edema and retinal vascular disease increases the value of efficient, repeatable OCT and multimodal imaging.

Finally, health-system procurement is becoming more enterprise-oriented. Larger ophthalmology networks increasingly standardize imaging equipment across locations, negotiate multi-device contracts and prioritize interoperability. Manufacturers able to provide hardware, analytics, image management, cybersecurity and scalable service contracts can compete for larger system-level opportunities than vendors offering isolated devices.

Innovation in Focus: How Manufacturers Are Raising the Bar

Innovation in the U.S. retinal disease diagnostic devices market is shifting from incremental improvements in image resolution toward complete diagnostic workflow redesign.

Swept-source OCT is one of the most important technology developments. Compared with earlier OCT architectures, swept-source systems can offer faster imaging, deeper penetration and broader visualization. These capabilities are particularly valuable when imaging deeper retinal and choroidal structures or patients with media opacity. Topcon’s Triton platform, for example, operates at approximately 100,000 A-scans per second using a 1,050-nm wavelength and combines swept-source OCT with retinal imaging modalities.

OCT angiography is another important innovation layer because it provides non-invasive visualization of retinal and choroidal microvasculature without requiring dye injection. OCTA is increasingly relevant for evaluating vascular abnormalities associated with diabetic retinopathy, neovascular AMD and retinal vascular disease. While it does not eliminate conventional angiography in every clinical situation, it expands the information obtained during routine OCT encounters.

High-performance platforms are also increasing scan width and acquisition speed. ZEISS CIRRUS 6000 can perform 100,000 scans per second and supports retinal OCTA scans as large as 12 × 12 mm. These specifications reflect the competitive direction of the market: manufacturers are attempting to capture more clinically relevant anatomy while reducing acquisition time.

Ultra-widefield imaging is expanding the diagnostic field beyond the posterior pole. Conventional fundus photography can miss peripheral pathology, whereas ultra-widefield technologies allow clinicians to assess substantially more retinal area in a single capture. This has particular relevance for diabetic retinopathy, retinal tears, peripheral lesions, vascular abnormalities and other conditions where disease may extend beyond the macula.

Multimodal imaging convergence is likely to be one of the strongest capital-equipment trends through 2035. Rather than purchasing a separate OCT, fundus camera, autofluorescence system and angiography platform, higher-volume centers increasingly value systems capable of performing multiple imaging functions. The economic benefit is not merely reduced equipment count; integrated platforms can simplify technician training, reduce patient transfers, align image registration and support more consistent longitudinal interpretation.

Automation is becoming equally important. Topcon Maestro2, for example, combines robotic OCT and fundus photography with automated alignment, focusing and acquisition, while providing a 12 × 9 mm 3D scan. Automation can broaden the group of staff capable of obtaining diagnostically usable images and can reduce variability across multi-site practice networks.

Artificial intelligence represents the most disruptive workflow innovation. FDA-cleared retinal diagnostic software systems can analyze digital fundus images for diabetic retinopathy screening. Regulatory records demonstrate multiple competing systems in this category, including products from Digital Diagnostics, AEYE Health, Eyenuk and iHealthScreen. This is important strategically because the long-term commercial model may shift from selling imaging hardware to ophthalmologists toward selling integrated acquisition-plus-analysis solutions to much larger primary-care and diabetes-care networks.

Home OCT may become another major growth frontier. In May 2024, the FDA granted De Novo classification to the Notal Vision Home Optical Coherence Tomography System, establishing a dedicated category for prescription self-imaging ophthalmic OCT systems incorporating automated image processing and analysis. This regulatory development is strategically important because it creates a pathway for selected retinal monitoring to move from periodic clinic imaging toward significantly more frequent home-based measurement.

Home imaging could change retinal-care economics if it allows clinicians to identify meaningful anatomical changes between routine appointments and selectively bring patients into the clinic when intervention is necessary. The commercial opportunity extends beyond hardware to patient onboarding, cloud infrastructure, algorithms, clinician dashboards, service contracts and data-management platforms.

The final innovation axis is longitudinal analytics. Retina specialists increasingly value the ability to compare identical retinal locations across multiple visits, automatically quantify changes and visualize trends. As therapies become more personalized, the value of a diagnostic platform will increasingly depend on the quality of its historical patient dataset and analytical software rather than raw image resolution alone.

Segmentation Insights

The U.S. Retinal Disease Diagnostic Devices Market is segmented on the basis of device type, disease indication, technology, end user and region.

By Device Type

Optical Coherence Tomography Systems

OCT systems represent the largest value-generating device category because they are deeply embedded in medical retina diagnosis and follow-up. The segment includes spectral-domain OCT, swept-source OCT, integrated OCT/fundus systems and OCT angiography-enabled platforms. OCT commands significant capital value while also creating recurring opportunities through software, upgrades and service.

The strongest purchasing drivers are scan speed, repeatability, image quality, segmentation accuracy, scan width, automated follow-up registration and workflow efficiency. High-volume retina practices may perform large numbers of OCT examinations every day, making acquisition speed and technician productivity economically meaningful.

Fundus Cameras and Ultra-Widefield Imaging Systems

Fundus cameras remain essential to retinal documentation, screening and teleophthalmology. The category includes mydriatic and non-mydriatic cameras, desktop systems, handheld retinal cameras and ultra-widefield platforms.

The growth profile is bifurcated. Premium ultra-widefield devices are gaining importance in retina specialist environments, while compact non-mydriatic cameras are expanding in diabetes screening, optometry and primary-care applications. Device manufacturers that simplify acquisition and consistently produce gradable images can access a much larger non-specialist user base.

Scanning Laser and Multimodal Retinal Imaging Platforms

Scanning laser ophthalmoscopy and multimodal retinal platforms occupy a premium clinical segment. These systems can integrate OCT, autofluorescence, infrared imaging, angiography and widefield visualization, making them attractive to academic eye centers and advanced retina practices.

Their value proposition is strongest where clinicians manage complex disease populations and need multiple diagnostic modalities during a single visit. Capital cost may be higher, but the ability to consolidate imaging workflows can support favorable economics in large retinal centers.

Ophthalmic Ultrasound and Specialty Posterior-Segment Diagnostic Devices

B-scan ultrasonography remains clinically important when direct optical visualization is impaired by dense cataract, vitreous hemorrhage or other media opacity. Although ultrasound represents a smaller revenue pool than OCT, it remains an essential diagnostic capability in vitreoretinal and ocular emergency care.

Specialty devices used for retinal electrophysiology, dark adaptation, pediatric retinal imaging and inherited retinal disease evaluation also contribute to the market. These categories have lower unit volume but serve clinically important niches.

Portable and Handheld Retinal Diagnostic Devices

Portable retinal imaging is expected to outperform the broader market as screening migrates outside traditional ophthalmology offices. Handheld cameras are particularly relevant for community programs, pediatric imaging, bedside hospital examinations, rural care and teleophthalmology.

The commercial requirements differ from premium retina platforms. Buyers prioritize ease of use, portability, rapid capture, low maintenance, wireless connectivity and dependable image quality.

AI-Enabled and Home Retinal Diagnostic Systems

AI-enabled retinal screening and home OCT represent the market’s most disruptive device-and-software category. These technologies can alter where diagnostic testing occurs and who operates the system.

The long-term value pool may be substantial because revenues can include equipment, software licensing, per-exam fees, remote monitoring services and clinical-data infrastructure. FDA recognition of both diabetic retinopathy diagnostic software and home ophthalmic OCT as distinct device categories materially improves the commercialization pathway.

By Disease Indication

Age-Related Macular Degeneration

AMD is the largest high-value retinal diagnostic indication. Approximately 19.8 million Americans aged 40 and older were estimated to have AMD in 2019, including approximately 1.49 million with vision-threatening disease. Florida showed the highest crude state prevalence in the CDC analysis, at approximately 18.3%, illustrating how aging demographics influence geographic demand.

AMD generates strong OCT demand because structural imaging is central to diagnosis and longitudinal disease management. Autofluorescence, OCTA, color imaging and multimodal imaging are also important for characterizing disease phenotype and progression.

Diabetic Retinopathy and Diabetic Macular Edema

Diabetic retinal disease represents the largest scalable screening opportunity. Approximately 9.6 million people were estimated to have diabetic retinopathy in the U.S. in 2021, including about 1.84 million with vision-threatening disease. The addressable population is expanding alongside the national diabetes burden.

This indication supports demand across two very different customer groups: specialist retina clinics requiring advanced OCT and multimodal imaging, and non-specialist settings requiring simple fundus acquisition combined with automated image interpretation.

Retinal Vascular Diseases

Retinal vein occlusion, retinal arterial disorders and other vascular abnormalities generate recurring requirements for OCT, OCTA, fundus photography and angiographic assessment. These patients can require repeated imaging because macular edema, ischemia and neovascular complications may evolve over time.

The market opportunity is concentrated in medical retina practices and large ophthalmology centers where imaging supports diagnosis, treatment planning and follow-up.

Retinal Detachment and Vitreoretinal Disorders

Retinal tears, posterior vitreous detachment, rhegmatogenous retinal detachment, vitreous hemorrhage, epiretinal membranes and macular holes represent another meaningful diagnostic category. Published epidemiological literature places rhegmatogenous retinal detachment incidence broadly in the range of approximately 6–18 cases per 100,000 people annually, with risk increasing in older populations.

Ultra-widefield imaging, OCT and ophthalmic ultrasound are particularly relevant because these disorders may involve peripheral retina, vitreoretinal interfaces or media opacity.

Inherited Retinal Disease and Other Retinal Disorders

Inherited retinal diseases, geographic atrophy, inflammatory retinal disorders, retinal toxicity and other less prevalent conditions constitute a smaller but technology-intensive segment. These disorders often require high-quality multimodal imaging and precise longitudinal comparison.

As genetic and disease-modifying therapies advance, diagnostic imaging may become increasingly important for patient selection and objective monitoring, providing a premium niche opportunity for manufacturers with highly reproducible imaging platforms.

By Technology

Spectral-Domain OCT

Spectral-domain OCT remains the largest installed technology base and will continue generating substantial replacement demand. Its advantages include strong resolution, established clinical familiarity, large normative datasets and broad availability across ophthalmology and optometry.

The segment will remain commercially important even as newer architectures gain share because a large installed base and extensive physician familiarity support continued use.

Swept-Source OCT

Swept-source OCT is expected to be one of the fastest-growing premium technologies through 2035. Faster acquisition, longer wavelengths and deeper penetration can support enhanced visualization of retinal and choroidal structures and improve imaging in selected patients with media opacity.

As price premiums moderate and multimodal integration improves, swept-source systems are expected to penetrate beyond academic centers into larger community retina practices.

OCT Angiography

OCTA is transitioning from a differentiating premium feature toward an increasingly important retinal vascular imaging capability. It allows non-invasive visualization of vascular networks and supports assessment of neovascularization and microvascular disease.

Future adoption will depend on acquisition speed, artifact management, scan coverage, segmentation accuracy and ability to integrate OCTA findings with structural OCT.

Fundus Photography, Autofluorescence and Ultra-Widefield Imaging

Color photography remains central to documentation and diabetic retinal screening. Autofluorescence provides additional information in conditions involving retinal pigment epithelium and geographic atrophy, while ultra-widefield imaging improves visualization of peripheral retinal pathology.

The strongest systems increasingly combine several of these modalities rather than forcing clinicians to use separate devices.

AI-Enabled Analysis, Tele-Retina and Connected Imaging

AI-enabled image analysis is projected to record the fastest technology growth. The FDA’s current diabetic retinopathy diagnostic software category includes several manufacturers, establishing a competitive U.S. ecosystem rather than a single-product market.

Connected retinal imaging also enables tele-retina programs in which acquisition occurs in one location and interpretation or clinical escalation occurs remotely. Over the forecast period, connectivity and automated triage are expected to become increasingly important product-selection criteria.

By End User

Hospitals and Academic Eye Centers

Hospitals and academic ophthalmology centers represent the highest-acuity end-user segment. These facilities require advanced multimodal platforms for complex disease, clinical research, emergency eye care and specialty referrals.

Procurement is evidence-intensive. Buyers often evaluate image quality, service infrastructure, interoperability, research capabilities, upgradeability and compatibility with clinical trials.

Retina Specialty Clinics

Retina specialty practices represent the most strategically important commercial segment because imaging intensity per patient is high. OCT, ultra-widefield imaging, angiography and multimodal platforms are embedded directly into patient flow.

For these buyers, throughput matters almost as much as image performance. A few seconds saved per acquisition can become economically meaningful across hundreds of examinations.

Comprehensive Ophthalmology and Optometry Practices

Comprehensive eye-care practices constitute a large installed-base opportunity. These facilities use OCT and fundus imaging to detect retinal disease, determine whether referral is needed and monitor appropriate patients.

Compact combined OCT/fundus systems are especially attractive because they provide broader diagnostic capability without requiring the space or complexity of a tertiary retina center.

Diabetes, Endocrinology and Primary-Care Screening Sites

This segment is expected to show rapid growth because diabetic retinopathy screening can increasingly be performed using automated cameras and AI analysis in non-ophthalmic settings.

The purchasing criteria are simplicity, imageability, training requirements, automated interpretation, integration with electronic records and referral workflow rather than advanced subspecialty imaging.

Teleophthalmology and Home Monitoring

Teleophthalmology and home monitoring currently represent a smaller share of total market revenue but offer substantial disruptive potential.

The FDA’s creation of a regulatory category for home OCT indicates that retinal monitoring can extend beyond the clinic in selected situations. If clinical adoption scales, manufacturers will compete on patient usability, connectivity, algorithm performance, adherence and clinician workflow integration rather than conventional equipment specifications alone.

Regional Insights: Where the Market Is Growing Fastest

The U.S. Retinal Disease Diagnostic Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional differences are shaped by diabetes prevalence, age structure, population growth, retina-specialist density, academic medical-center concentration, outpatient ophthalmology infrastructure, insurance coverage, health-system consolidation and adoption of advanced imaging.

The South is estimated to represent the largest regional market in 2025, while the West is expected to record the fastest growth through 2035. The Northeast remains a premium technology and academic-adoption market, while the Midwest provides a large installed base of ophthalmology and health-system demand.

South

The South is estimated at approximately USD 0.61 billion in 2025, representing about 34.9% of U.S. market revenue, and is projected to reach approximately USD 1.61 billion by 2035, implying growth broadly around 10.2% annually.

The regional definition includes Texas, Florida, Georgia, North Carolina, Tennessee, South Carolina, Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, Virginia, Maryland and West Virginia.

The South’s leadership is supported by population scale, aging, high diabetes burden in multiple states and expanding outpatient healthcare infrastructure. Florida is particularly important for AMD diagnostics because of its older population. CDC modeling estimated Florida had the highest crude AMD prevalence among states, approximately 18.3%, making the state structurally attractive for OCT, fundus imaging, geographic-atrophy documentation and longitudinal retinal monitoring.

Florida is expected to remain one of the largest U.S. retinal diagnostic device markets. Demand is concentrated around Miami, Tampa, Orlando, Jacksonville, Fort Lauderdale and other retirement-heavy metropolitan areas. Retina practices serving older populations generate strong recurring OCT and retinal imaging utilization.

Texas is another major state opportunity because its large population, substantial diabetes burden, extensive hospital infrastructure and rapidly expanding metropolitan areas create demand across both advanced retina practices and scalable diabetic eye-screening programs. Houston, Dallas-Fort Worth, San Antonio and Austin are particularly important commercial hubs.

North Carolina, Georgia and Tennessee are increasingly attractive because population growth is combining with academic ophthalmology networks and consolidated specialty practices. These states are expected to show above-average demand for automated OCT, multi-location imaging systems and tele-retina infrastructure.

Virginia and Maryland benefit from strong specialist networks, affluent metropolitan populations and proximity to academic and federal healthcare infrastructure. Premium retinal imaging adoption is relatively strong.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma and West Virginia represent strategically important screening markets. Diabetes prevalence, rural access limitations and lower specialist density increase the relevance of portable cameras, teleophthalmology and automated referral systems. Manufacturers that rely solely on premium tertiary-care equipment may underpenetrate these markets; compact and remotely connected solutions may offer better scalability.

The South should retain the largest absolute revenue pool through 2035 because it combines high disease burden with large population growth. The strongest opportunities will include diabetic retinal screening networks, automated fundus cameras, replacement OCT systems, retina-practice consolidation and home-monitoring adoption among older patients.

West

The West is estimated at approximately USD 0.40 billion in 2025 and is projected to reach approximately USD 1.17 billion by 2035, corresponding to an estimated 11.3% CAGR, the fastest among the four major regions.

The regional definition includes California, Washington, Arizona, Colorado, Oregon, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

California is the dominant state market and one of the most strategically influential retinal imaging markets nationally. Its importance comes from a combination of population size, academic ophthalmology centers, large integrated health systems, technology adoption, venture-backed digital health activity and sophisticated specialty practices.

California is particularly favorable for AI-based retinal screening, connected diagnostics, ultra-widefield imaging and premium multimodal systems. Large provider organizations can evaluate technology at enterprise scale, creating opportunities for manufacturers offering integrated device, software and cloud ecosystems.

Arizona is a high-growth retirement and population-migration market. Its older demographic profile supports AMD diagnostics, while diabetes adds demand for retinal screening.

Nevada is another high-growth population market. CDC modeling of diabetic retinopathy showed meaningful state-level variation; among people with diabetes, estimated crude DR prevalence ranged from approximately 20.8% in Nevada to 31.3% in Massachusetts, emphasizing that retinal diagnostic demand varies considerably even within a large national disease pool.

Washington and Oregon are attractive for connected ophthalmology, integrated health systems and digital workflow adoption. Teleophthalmology and cloud-based retinal image management are likely to find relatively favorable operating environments.

Colorado and Utah combine expanding populations with sophisticated healthcare delivery systems. Premium imaging and multi-site ophthalmology networks should contribute to above-average growth.

New Mexico, Idaho, Montana, Wyoming and Alaska have smaller equipment markets but present specific opportunities for portable retinal cameras and tele-retina because geographic distance can make specialist access difficult.

The West’s growth leadership will be driven less by disease burden alone and more by technology intensity. AI-assisted retinal analysis, home monitoring, connected imaging, swept-source OCT and multimodal systems are expected to penetrate particularly quickly in this region.

Northeast

The Northeast is estimated at approximately USD 0.42 billion in 2025, making it the second-largest region by value, and is projected to reach approximately USD 1.04 billion by 2035, representing a CAGR of around 9.5%.

The region includes New York, Massachusetts, Pennsylvania, New Jersey, Connecticut, Maine, Vermont, New Hampshire, Rhode Island and Delaware.

The Northeast’s primary market advantage is clinical sophistication. The region contains a high concentration of academic medical centers, retina specialists, ophthalmology residency programs and research infrastructure. This supports premium diagnostic equipment and early evaluation of advanced technologies.

New York is the largest state market in the region. New York City and surrounding metropolitan areas support substantial volumes of retina imaging, while upstate networks create additional opportunities for teleophthalmology and multi-site equipment deployment.

Massachusetts is disproportionately important relative to its population because of its concentration of academic medicine and biomedical innovation. CDC analysis estimated Massachusetts had the highest crude diabetic retinopathy prevalence among people with diabetes at approximately 31.3%, further reinforcing the state’s retinal screening relevance.

Pennsylvania and New Jersey provide large, mature ophthalmology markets and substantial older populations. Integrated health systems and multisite physician organizations create meaningful enterprise procurement opportunities.

Connecticut, Rhode Island, Maine, New Hampshire and Vermont are smaller markets, but older demographics in parts of New England support AMD imaging demand. Rural areas also create a rationale for remote image interpretation and connected screening.

The Northeast may grow more slowly than the West because the installed base is mature, but revenue per site is likely to remain attractive. Academic and subspecialty centers frequently adopt premium imaging modules, software upgrades and advanced clinical analytics ahead of community markets.

Midwest

The Midwest is estimated at approximately USD 0.32 billion in 2025 and is expected to reach approximately USD 0.80 billion by 2035, representing growth of approximately 9.6% annually.

The region includes Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.

The Midwest represents a stable market combining large metropolitan ophthalmology systems with extensive regional and rural healthcare networks.

Illinois is the largest commercial hub, led by Chicago’s academic hospitals and large specialty-practice base.

Ohio has a strong ophthalmology infrastructure across Cleveland, Columbus and Cincinnati and is an important market for premium retinal imaging, diabetic screening and multisite health-system procurement.

Michigan contributes substantial demand through Detroit-area healthcare systems and a large chronic-disease population.

Minnesota has strategic relevance because of its medical-device ecosystem, sophisticated healthcare systems and strong adoption of integrated clinical technology.

Indiana, Wisconsin and Missouri provide stable demand across hospitals, community ophthalmology and optometry practices. Their commercial opportunity is likely to center on replacement OCT systems, combined imaging platforms and diabetic screening.

Iowa, Kansas, Nebraska, North Dakota and South Dakota have smaller absolute markets, but geographic dispersion creates a compelling use case for tele-retinal imaging, portable cameras and centralized image interpretation.

The Midwest is unlikely to lead the country in premium pricing or technology growth, but it should remain an important installed-base replacement market. Vendors offering reliability, service coverage, efficient equipment financing and scalable multi-site contracts are likely to perform particularly well.

Key Market Players

The U.S. Retinal Disease Diagnostic Devices competitive landscape combines multinational ophthalmic equipment manufacturers, specialist retinal imaging companies, diagnostic software developers and emerging home-monitoring companies.

Competition is increasingly platform-based. Traditional device manufacturers compete on scan performance, image quality, installed base, physician familiarity and service infrastructure. Newer software and remote-monitoring entrants compete on accessibility, automation, analytics and the ability to expand retinal diagnosis beyond specialist environments.

Some of the key players relevant to the U.S. retinal disease diagnostic devices ecosystem include:

Carl Zeiss Meditec AG
Topcon Healthcare
Heidelberg Engineering GmbH
Optos plc / Nikon Corporation
NIDEK Co., Ltd.
Canon Inc. / Canon Medical ophthalmic imaging operations
Kowa Company, Ltd.
Visionix / Optovue
iCare / CenterVue
Tomey Corporation
Huvitz Co., Ltd.
Phoenix Technology Group
Volk Optical
HEINE Optotechnik
Keeler Ltd.
Baxter / Welch Allyn
Digital Diagnostics Inc.
Eyenuk, Inc.
AEYE Health Inc.
iHealthScreen, Inc.
Notal Vision, Inc.
Remidio Innovative Solutions
Intalight
RetinAI Medical AG

Among these companies, ZEISS, Topcon, Heidelberg Engineering and Optos/Nikon are particularly strong in premium retina imaging because they offer mature installed bases and broad posterior-segment imaging capabilities. ZEISS competes heavily through OCT and connected ophthalmic workflows; Topcon combines OCT, fundus imaging and automated acquisition; Heidelberg Engineering is particularly strong in multimodal retina imaging; and Optos has differentiated itself through ultra-widefield retinal visualization.

The premium hardware market has meaningful barriers to entry. Clinicians accumulate longitudinal images on a platform, technicians become familiar with acquisition workflows and health systems integrate equipment into data infrastructure. Switching vendors therefore involves more than purchasing a new scanner. Data migration, training, physician preference and workflow disruption can influence procurement.

AI-focused companies are creating a parallel competitive layer. Digital Diagnostics, Eyenuk, AEYE Health and iHealthScreen have FDA-regulated diabetic retinopathy diagnostic systems or software, strengthening competition in decentralized retinal screening.

Notal Vision occupies a strategically important position in home retinal monitoring following FDA De Novo authorization of its home OCT system. The significance extends beyond one company because the regulatory pathway creates a defined category that future competitors may seek to enter.

Competitive advantage through 2035 will increasingly depend on six factors: image quality, automation, clinical evidence, data portability, connected workflow and lifecycle economics. Companies that combine these capabilities are likely to gain stronger enterprise contracts than vendors competing primarily on device acquisition price.

Recent Developments

Recent developments indicate that U.S. retinal diagnostics are moving simultaneously toward higher-performance specialist imaging and wider access outside the specialist clinic.

One important development has been the regulatory maturation of home OCT. On May 15, 2024, the FDA granted De Novo authorization to the Notal Vision Home Optical Coherence Tomography System. The corresponding regulatory category defines a prescription self-imaging device incorporating OCT hardware and automated image analysis for physician monitoring between scheduled assessments. This represents a major structural development because it establishes a framework for moving selected retinal monitoring into the home.

AI-enabled diabetic retinopathy screening also continued to expand. AEYE-DS received a substantially equivalent FDA decision on April 23, 2024, adding to a regulatory category already containing systems from other autonomous retinal diagnostic developers.

In July 2026, the FDA issued a substantially equivalent decision for iHealthScreen’s iPredict-DR, further broadening competition within diabetic retinopathy diagnostic software. The increasing number of regulated systems indicates that autonomous retinal screening is becoming a sustainable device category rather than a single-company exception.

Premium OCT innovation is continuing in parallel. In May 2026, the FDA issued a substantially equivalent decision for Heidelberg Engineering’s SPECTRALIS HRA+OCT and variants, including the SPECTRALIS with Flex Module. The development reinforces continuing regulatory and product activity within advanced multimodal retinal imaging.

ZEISS has also continued to strengthen the CIRRUS 6000 platform. Recent enhancements expanded its U.S. OCT reference database to 870 healthy eyes, alongside workflow and cybersecurity improvements. Modern retinal imaging competition is therefore extending beyond optical specifications toward reference datasets, analytics and cybersecurity.

Topcon continues to emphasize combined robotic OCT and fundus-camera workflows. Its Maestro2 platform integrates automated acquisition with OCT, true-color fundus photography and optional OCT angiography, reflecting the broader industry shift toward fewer technician steps and consolidated diagnostic workstations.

The broader implication is that the retinal diagnostic market is splitting into two complementary technology trajectories. Specialist practices are adopting increasingly sophisticated multimodal platforms, while screening environments are adopting progressively simpler automated devices. Manufacturers able to serve both workflows through common data infrastructure may ultimately gain a significant competitive advantage.

Conclusion

The U.S. Retinal Disease Diagnostic Devices Market Size & Share is positioned for strong expansion from an estimated USD 1.75 billion in 2025 to approximately USD 4.62 billion by 2035, representing a 10.20% CAGR during 2026–2035.

The market’s long-term strength is supported by several structural factors that are unlikely to reverse: a large AMD population, growing diabetes burden, demographic aging, increasing dependence on quantitative retinal imaging, regular treatment-response monitoring, replacement of earlier-generation OCT equipment, expansion of multimodal imaging and growing acceptance of automated retinal screening.

The most important commercial shift is from device-centric imaging to diagnostic ecosystems. The winning technology platforms will increasingly combine high-quality acquisition with analytics, automation, longitudinal comparison, image management and clinical workflow integration.

OCT will remain the market’s core revenue engine, but value growth will increasingly migrate toward swept-source imaging, OCT angiography, ultra-widefield visualization, multimodal systems and intelligent analytics. Spectral-domain OCT will continue to generate significant replacement demand, particularly among comprehensive ophthalmology and community practices.

AI-enabled diabetic retinopathy screening represents a different type of opportunity. Instead of competing for the same retina-specialist capital budgets, AI-enabled systems can expand retinal diagnostics into endocrinology, primary care and community environments. With approximately 40.1 million Americans estimated to have diabetes in 2023, even incremental improvement in retinal screening penetration can create substantial equipment and software demand.

Home retinal monitoring could become an equally important long-term category. The establishment of an FDA home OCT classification provides regulatory validation for a new care model in which high-risk retinal patients generate clinically useful imaging between office visits. Commercial success will depend on reimbursement economics, patient adherence, physician workload, algorithm accuracy and integration with retina-practice workflows.

Regional opportunity will remain concentrated in the South, estimated at USD 0.61 billion in 2025, because of population scale, diabetes burden and the large older population in states such as Florida. The West, estimated at USD 0.40 billion, is projected to grow fastest as California and other technology-intensive markets adopt AI, connected imaging and advanced OCT platforms. The Northeast, at approximately USD 0.42 billion, will remain a premium academic and specialist market, while the Midwest, at approximately USD 0.32 billion, provides a stable equipment replacement and tele-retina opportunity.

At the state level, California, Florida, Texas, New York, Pennsylvania, Massachusetts, New Jersey, Illinois, Ohio, Michigan, North Carolina, Georgia, Arizona, Virginia, Washington and Minnesota should remain particularly important commercial territories. Florida’s elevated AMD burden, Massachusetts’ high estimated diabetic retinopathy prevalence among people with diabetes, California’s technology ecosystem and Texas’ population scale illustrate why a single national sales strategy is unlikely to maximize market penetration.

For manufacturers, the most attractive strategic opportunities will be found where a diagnostic device solves a measurable workflow problem. Faster acquisition, fewer rescans, reliable segmentation, automated patient positioning, broader retinal coverage, earlier identification of disease, remote interpretation and reduced unnecessary referral burden all translate clinical innovation into economic value.

For health systems and ophthalmology groups, purchasing decisions will increasingly focus on lifecycle economics rather than acquisition price. Capital cost must be balanced against equipment utilization, staff time, physician throughput, software fees, service contracts, interoperability and useful device life.

For investors and market entrants, the key distinction is between mature equipment replacement and market-creating innovation. Conventional fundus photography and spectral-domain OCT provide predictable installed-base demand. Swept-source OCT, autonomous AI screening, multimodal imaging and home OCT have greater potential to expand the underlying diagnostic market itself.

The defining competitive advantage through 2035 will therefore not be the ability to produce the sharpest retinal image in isolation. It will be the ability to turn retinal images into earlier identification, more confident clinical decisions, efficient monitoring and scalable access to eye care.

Companies that successfully combine optical engineering, clinical evidence, automated acquisition, regulatory execution, digital connectivity and longitudinal analytics are expected to capture a disproportionate share of the next growth cycle in the U.S. Retinal Disease Diagnostic Devices Market.

TABLE OF CONTENT

1. U.S. Retinal Disease Diagnostic Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Analytical Frameworks & Forecasting Models
1.3.6. Data Triangulation, Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Retinal Diagnostic Device Manufacturers
1.6.2. Optical, Imaging Sensor and Component Suppliers
1.6.3. Ophthalmology Hospitals and Academic Eye Centers
1.6.4. Retina Specialty Practices and Ophthalmology Groups
1.6.5. Optometry Practices and Community Eye-Care Providers
1.6.6. Diabetes, Endocrinology and Primary-Care Screening Networks
1.6.7. Teleophthalmology and Remote Retinal Monitoring Providers
1.6.8. Distributors, Group Purchasing Organizations and Channel Partners
1.6.9. Payers, FDA, CMS and Clinical Decision-Makers

What this section provides: This section defines the U.S. retinal disease diagnostic devices market boundary, research scope, methodology, analytical assumptions and stakeholder ecosystem, helping clients understand how device revenues, diagnostic technologies and market forecasts are measured and validated.

2. U.S. Retinal Disease Diagnostic Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size, 2021–2035 (US$ Billion)
2.8. CAGR Analysis, 2026–2035
2.9. High-Growth Opportunity Areas
2.10. Key Technology Adoption Themes
2.11. Priority Customer and Procurement Opportunities

What this section provides: This section gives decision-makers a concise view of market size, historical development, 2025 positioning, 2026–2035 growth expectations, key technology shifts, competitive intensity and the highest-value commercial opportunities.

3. U.S. Retinal Disease Diagnostic Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis

3.1.1. Rising Burden of Age-Related Macular Degeneration
3.1.2. Growing Diabetes and Diabetic Retinopathy Screening Population
3.1.3. Aging U.S. Population and Increasing Retinal Disease Risk
3.1.4. Increasing Clinical Dependence on Optical Coherence Tomography
3.1.5. Expansion of Repeat Retinal Imaging and Treatment Monitoring
3.1.6. Growing Adoption of Multimodal Retinal Imaging
3.1.7. Expansion of AI-Enabled Diabetic Retinopathy Screening
3.1.8. Growth of Tele-Retina and Decentralized Screening Models

3.2. Restraints and Their Impact Analysis

3.2.1. High Capital Cost of Premium OCT and Multimodal Platforms
3.2.2. Reimbursement Pressure for Retinal Diagnostic Procedures
3.2.3. Budget Constraints Among Smaller Ophthalmology Practices
3.2.4. Image Interoperability and Data Migration Challenges
3.2.5. Limited Specialist and Ophthalmic Technician Availability
3.2.6. Regulatory and Clinical Validation Requirements for AI Diagnostics

3.3. Opportunities and Their Impact Analysis

3.3.1. Swept-Source OCT Replacement Cycle
3.3.2. OCT Angiography Adoption
3.3.3. Autonomous AI-Based Diabetic Retinopathy Screening
3.3.4. Ultra-Widefield Retinal Imaging Expansion
3.3.5. Portable and Handheld Retinal Imaging
3.3.6. Home OCT and Remote Retinal Monitoring
3.3.7. Rural and Underserved Retinal Screening Programs
3.3.8. Enterprise Ophthalmology Imaging and Data Platforms

3.4. Challenges and Their Impact Analysis

3.4.1. Variability in Image Quality Across Patient Populations
3.4.2. AI Algorithm Generalizability and False Referral Risk
3.4.3. Device Integration with EHR and Ophthalmic Image Management Systems
3.4.4. Cybersecurity and Patient Data Protection
3.4.5. Uneven Access to Retina Specialists Across U.S. States

3.5. Patent & Innovation Analysis, 2021–2025
3.6. Retinal Imaging Clinical Workflow Economics Analysis
3.7. Ophthalmology Capital Procurement Behavior Analysis
3.8. Retina Practice Equipment Replacement Cycle Analysis
3.9. Diagnostic Procedure Economics and Utilization Trends

What this section provides: This section evaluates the clinical, demographic, economic, technological and operational forces shaping retinal diagnostic device demand and helps clients identify growth catalysts, adoption barriers and execution risks.

4. U.S. Retinal Disease Diagnostic Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis

4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis

4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitution
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Device Type, 2025–2035
4.4. Pricing Trend Analysis by Region, 2025–2035
4.5. Value Chain & Supply Chain Analysis
4.6. Optical Components, Cameras, Sensors and Semiconductor Supply Analysis
4.7. Impact of Digitalization and Connected Ophthalmology
4.8. Retinal Imaging & Innovation Landscape
4.9. Artificial Intelligence Diagnostic Ecosystem
4.10. FDA Regulatory Framework Analysis
4.11. FDA 510(k), De Novo and Software Regulatory Pathways
4.12. CMS Reimbursement and Coverage Landscape
4.13. Retinal Imaging Coding and Payment Environment
4.14. Import/Export Restrictions & Tariff Impact
4.15. Government Initiatives and Vision-Screening Programs
4.16. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.17. Ophthalmology Value Analysis and Capital Equipment Decision Framework

What this section provides: This section provides a complete assessment of the regulatory, reimbursement, pricing, technology, supply-chain and procurement environment affecting retinal disease diagnostic device commercialization in the United States.

5. U.S. Retinal Disease Diagnostic Devices Market – By Device Type

5.1. Overview
5.1.1. Segment Share Analysis, By Device Type, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)

5.2. Optical Coherence Tomography Systems

5.2.1. Spectral-Domain OCT Systems
5.2.2. Swept-Source OCT Systems
5.2.3. Integrated OCT and Fundus Imaging Systems
5.2.4. OCT Angiography-Enabled Platforms

5.3. Fundus Imaging Systems

5.3.1. Mydriatic Fundus Cameras
5.3.2. Non-Mydriatic Fundus Cameras
5.3.3. Digital Retinal Cameras
5.3.4. Portable and Handheld Fundus Cameras

5.4. Ultra-Widefield Retinal Imaging Systems

5.4.1. Ultra-Widefield Color Imaging
5.4.2. Ultra-Widefield Autofluorescence Imaging
5.4.3. Integrated Ultra-Widefield OCT Platforms

5.5. Scanning Laser & Multimodal Retinal Imaging Systems

5.5.1. Scanning Laser Ophthalmoscopy Systems
5.5.2. Fundus Autofluorescence Systems
5.5.3. Fluorescein Angiography-Enabled Platforms
5.5.4. Indocyanine Green Angiography-Enabled Platforms
5.5.5. Multimodal Retinal Imaging Workstations

5.6. Ophthalmic Ultrasound Systems

5.6.1. B-Scan Ophthalmic Ultrasound
5.6.2. A/B-Scan Combination Systems
5.6.3. Portable Ophthalmic Ultrasound

5.7. AI-Enabled and Remote Retinal Diagnostic Systems

5.7.1. Autonomous Retinal Diagnostic Systems
5.7.2. AI-Assisted Retinal Image Analysis Platforms
5.7.3. Home OCT Systems
5.7.4. Remote Retinal Monitoring Platforms

5.8. Other Retinal Diagnostic Devices

5.8.1. Retinal Electrophysiology Systems
5.8.2. Dark Adaptometry Devices
5.8.3. Pediatric Retinal Imaging Systems
5.8.4. Specialty Retinal Diagnostic Systems

What this section provides: This section identifies the retinal diagnostic device categories generating the highest revenue, installed-base replacement demand and technology-driven growth through 2035.

6. U.S. Retinal Disease Diagnostic Devices Market – By Disease Indication

6.1. Overview
6.1.1. Segment Share Analysis, By Disease Indication, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Disease Indication, 2021–2035 (US$ Billion)

6.2. Age-Related Macular Degeneration

6.2.1. Early and Intermediate AMD
6.2.2. Neovascular/Wet AMD
6.2.3. Geographic Atrophy/Dry AMD

6.3. Diabetic Retinal Disease

6.3.1. Non-Proliferative Diabetic Retinopathy
6.3.2. Proliferative Diabetic Retinopathy
6.3.3. Diabetic Macular Edema

6.4. Retinal Vascular Diseases

6.4.1. Retinal Vein Occlusion
6.4.2. Retinal Artery Occlusion
6.4.3. Retinal Ischemic and Microvascular Disorders

6.5. Retinal Detachment & Vitreoretinal Disorders

6.5.1. Retinal Tears
6.5.2. Rhegmatogenous Retinal Detachment
6.5.3. Posterior Vitreous Detachment
6.5.4. Vitreous Hemorrhage
6.5.5. Epiretinal Membrane
6.5.6. Macular Hole

6.6. Inherited and Other Retinal Diseases

6.6.1. Retinitis Pigmentosa
6.6.2. Stargardt Disease
6.6.3. Other Inherited Retinal Diseases
6.6.4. Inflammatory Retinal Disorders
6.6.5. Drug- and Toxicity-Related Retinal Disorders
6.6.6. Other Retinal Conditions

What this section provides: This section quantifies diagnostic demand by retinal disease and helps clients identify indications generating the strongest screening, repeat-imaging and longitudinal monitoring opportunities.

7. U.S. Retinal Disease Diagnostic Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

7.2. Hospitals and Academic Eye Centers

7.2.1. Academic Medical Centers
7.2.2. University Eye Hospitals
7.2.3. Integrated Hospital Ophthalmology Departments

7.3. Retina Specialty Clinics

7.3.1. Independent Retina Practices
7.3.2. Multisite Retina Groups
7.3.3. Private Equity-Backed Ophthalmology Platforms

7.4. Comprehensive Ophthalmology & Optometry Practices

7.4.1. Comprehensive Ophthalmology Clinics
7.4.2. Multispecialty Eye-Care Practices
7.4.3. Optometry Practices

7.5. Diabetes, Endocrinology & Primary-Care Screening Sites

7.5.1. Endocrinology Clinics
7.5.2. Primary-Care Practices
7.5.3. Federally Qualified Health Centers
7.5.4. Community Diabetes Programs

7.6. Teleophthalmology & Remote Monitoring Providers

7.6.1. Tele-Retinal Screening Networks
7.6.2. Remote Image Reading Services
7.6.3. Home OCT Monitoring Programs
7.6.4. Connected Retinal Diagnostic Platforms

What this section provides: This section identifies the care settings responsible for device purchasing, diagnostic utilization and recurring retinal imaging demand and evaluates how decentralized screening is changing the traditional ophthalmology customer base.

8. U.S. Retinal Disease Diagnostic Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)

8.2. Spectral-Domain OCT

8.2.1. Standard SD-OCT
8.2.2. High-Speed SD-OCT
8.2.3. SD-OCT with Integrated Fundus Imaging

8.3. Swept-Source OCT

8.3.1. Conventional Swept-Source OCT
8.3.2. Widefield Swept-Source OCT
8.3.3. Multimodal Swept-Source OCT

8.4. OCT Angiography

8.4.1. Macular OCTA
8.4.2. Widefield OCTA
8.4.3. Quantitative OCTA Analytics

8.5. Fundus Photography, Autofluorescence & Ultra-Widefield Imaging

8.5.1. Digital Fundus Photography
8.5.2. Non-Mydriatic Imaging
8.5.3. Fundus Autofluorescence
8.5.4. Ultra-Widefield Retinal Imaging
8.5.5. Confocal Scanning Laser Imaging

8.6. AI-Enabled, Tele-Retina & Connected Imaging

8.6.1. Autonomous AI Diagnostics
8.6.2. AI-Assisted Retinal Image Interpretation
8.6.3. Cloud-Based Retinal Image Management
8.6.4. Tele-Retina Platforms
8.6.5. Home-Based Connected Retinal Imaging

What this section provides: This section evaluates the technology platforms transforming retinal disease diagnosis, from established spectral-domain OCT to swept-source imaging, OCT angiography, ultra-widefield visualization, AI and connected retinal diagnostics.

9. U.S. Retinal Disease Diagnostic Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

9.2. Direct Manufacturer Sales

9.2.1. Direct Capital Equipment Procurement
9.2.2. Manufacturer Service and Maintenance Contracts
9.2.3. Software and Upgrade Contracts

9.3. Health System and Enterprise Contracts

9.3.1. Integrated Delivery Network Procurement
9.3.2. Multisite Ophthalmology Group Contracts
9.3.3. Enterprise Imaging Platform Agreements

9.4. Group Purchasing Organization Contracts

9.4.1. Hospital GPO Contracts
9.4.2. Physician Group Purchasing Agreements

9.5. Distributor & Specialty Ophthalmic Supplier Sales

9.5.1. National Ophthalmic Distributors
9.5.2. Regional Specialty Distributors
9.5.3. Value-Added Resellers

9.6. Software, Subscription & Remote Diagnostic Procurement

9.6.1. Software-as-a-Service Contracts
9.6.2. Per-Screening/Per-Test Models
9.6.3. Remote Monitoring Subscription Models
9.6.4. Cloud Platform Licensing

What this section provides: This section explains how retinal diagnostic technologies are purchased in the U.S., including direct manufacturer sales, health-system standardization, GPO influence, specialty distribution and emerging subscription-based diagnostic models.

10. U.S. Retinal Disease Diagnostic Devices Market – By Geography

10.1. Introduction

10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Retinal Disease Burden Analysis
10.1.4. Regional Ophthalmology and Retina Specialist Infrastructure
10.1.5. Regional Retinal Imaging Procedure Utilization
10.1.6. Regional Reimbursement and Procurement Dynamics
10.1.7. Regional Technology Adoption Index
10.1.8. Regional AI and Tele-Retina Adoption Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers and Retinal Diagnostic Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Disease Indication, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Device Type, 2021–2035
10.2.9.3. California Market Size and Forecast, By Disease Indication, 2021–2035
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Device Type, 2021–2035
10.2.10.3. Washington Market Size and Forecast, By Disease Indication, 2021–2035
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Device Type, 2021–2035
10.2.11.3. Arizona Market Size and Forecast, By Disease Indication, 2021–2035
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Device Type, 2021–2035
10.2.12.3. Colorado Market Size and Forecast, By Disease Indication, 2021–2035
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Device Type, 2021–2035
10.2.13.3. Oregon Market Size and Forecast, By Disease Indication, 2021–2035
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Device Type, 2021–2035
10.2.14.3. Utah Market Size and Forecast, By Disease Indication, 2021–2035
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Device Type, 2021–2035
10.2.15.3. Nevada Market Size and Forecast, By Disease Indication, 2021–2035
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Device Type, 2021–2035
10.2.16.3. New Mexico Market Size and Forecast, By Disease Indication, 2021–2035
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Device Type, 2021–2035
10.2.17.3. Idaho Market Size and Forecast, By Disease Indication, 2021–2035
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Device Type, 2021–2035
10.2.18.3. Montana Market Size and Forecast, By Disease Indication, 2021–2035
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Device Type, 2021–2035
10.2.19.3. Wyoming Market Size and Forecast, By Disease Indication, 2021–2035
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Device Type, 2021–2035
10.2.20.3. Alaska Market Size and Forecast, By Disease Indication, 2021–2035
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Device Type, 2021–2035
10.2.21.3. Hawaii Market Size and Forecast, By Disease Indication, 2021–2035
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers and Retinal Diagnostic Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035
10.3.4. Northeast Region Market Size and Forecast, By Device Type, 2021–2035
10.3.5. Northeast Region Market Size and Forecast, By Disease Indication, 2021–2035
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. Market Size and Forecast, By Device Type
10.3.9.3. Market Size and Forecast, By Disease Indication
10.3.9.4. Market Size and Forecast, By End User
10.3.9.5. Market Size and Forecast, By Technology Type
10.3.9.6. Market Size and Forecast, By Procurement Channel

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Market Size and Forecast, By Device Type
10.3.10.3. Market Size and Forecast, By Disease Indication
10.3.10.4. Market Size and Forecast, By End User
10.3.10.5. Market Size and Forecast, By Technology Type
10.3.10.6. Market Size and Forecast, By Procurement Channel

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. Market Size and Forecast, By Device Type
10.3.11.3. Market Size and Forecast, By Disease Indication
10.3.11.4. Market Size and Forecast, By End User
10.3.11.5. Market Size and Forecast, By Technology Type
10.3.11.6. Market Size and Forecast, By Procurement Channel

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Market Size and Forecast, By Device Type
10.3.12.3. Market Size and Forecast, By Disease Indication
10.3.12.4. Market Size and Forecast, By End User
10.3.12.5. Market Size and Forecast, By Technology Type
10.3.12.6. Market Size and Forecast, By Procurement Channel

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Market Size and Forecast, By Device Type
10.3.13.3. Market Size and Forecast, By Disease Indication
10.3.13.4. Market Size and Forecast, By End User
10.3.13.5. Market Size and Forecast, By Technology Type
10.3.13.6. Market Size and Forecast, By Procurement Channel

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Market Size and Forecast, By Device Type
10.3.14.3. Market Size and Forecast, By Disease Indication
10.3.14.4. Market Size and Forecast, By End User
10.3.14.5. Market Size and Forecast, By Technology Type
10.3.14.6. Market Size and Forecast, By Procurement Channel

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Market Size and Forecast, By Device Type
10.3.15.3. Market Size and Forecast, By Disease Indication
10.3.15.4. Market Size and Forecast, By End User
10.3.15.5. Market Size and Forecast, By Technology Type
10.3.15.6. Market Size and Forecast, By Procurement Channel

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. Market Size and Forecast, By Device Type
10.3.16.3. Market Size and Forecast, By Disease Indication
10.3.16.4. Market Size and Forecast, By End User
10.3.16.5. Market Size and Forecast, By Technology Type
10.3.16.6. Market Size and Forecast, By Procurement Channel

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Market Size and Forecast, By Device Type
10.3.17.3. Market Size and Forecast, By Disease Indication
10.3.17.4. Market Size and Forecast, By End User
10.3.17.5. Market Size and Forecast, By Technology Type
10.3.17.6. Market Size and Forecast, By Procurement Channel

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers and Retinal Diagnostic Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035
10.4.4. South Region Market Size and Forecast, By Device Type, 2021–2035
10.4.5. South Region Market Size and Forecast, By Disease Indication, 2021–2035
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Market Size and Forecast, By Device Type
10.4.9.3. Market Size and Forecast, By Disease Indication
10.4.9.4. Market Size and Forecast, By End User
10.4.9.5. Market Size and Forecast, By Technology Type
10.4.9.6. Market Size and Forecast, By Procurement Channel

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Market Size and Forecast, By Device Type
10.4.10.3. Market Size and Forecast, By Disease Indication
10.4.10.4. Market Size and Forecast, By End User
10.4.10.5. Market Size and Forecast, By Technology Type
10.4.10.6. Market Size and Forecast, By Procurement Channel

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Market Size and Forecast, By Device Type
10.4.11.3. Market Size and Forecast, By Disease Indication
10.4.11.4. Market Size and Forecast, By End User
10.4.11.5. Market Size and Forecast, By Technology Type
10.4.11.6. Market Size and Forecast, By Procurement Channel

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. Market Size and Forecast, By Device Type
10.4.12.3. Market Size and Forecast, By Disease Indication
10.4.12.4. Market Size and Forecast, By End User
10.4.12.5. Market Size and Forecast, By Technology Type
10.4.12.6. Market Size and Forecast, By Procurement Channel

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Market Size and Forecast, By Device Type
10.4.13.3. Market Size and Forecast, By Disease Indication
10.4.13.4. Market Size and Forecast, By End User
10.4.13.5. Market Size and Forecast, By Technology Type
10.4.13.6. Market Size and Forecast, By Procurement Channel

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. Market Size and Forecast, By Device Type
10.4.14.3. Market Size and Forecast, By Disease Indication
10.4.14.4. Market Size and Forecast, By End User
10.4.14.5. Market Size and Forecast, By Technology Type
10.4.14.6. Market Size and Forecast, By Procurement Channel

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Market Size and Forecast, By Device Type
10.4.15.3. Market Size and Forecast, By Disease Indication
10.4.15.4. Market Size and Forecast, By End User
10.4.15.5. Market Size and Forecast, By Technology Type
10.4.15.6. Market Size and Forecast, By Procurement Channel

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Market Size and Forecast, By Device Type
10.4.16.3. Market Size and Forecast, By Disease Indication
10.4.16.4. Market Size and Forecast, By End User
10.4.16.5. Market Size and Forecast, By Technology Type
10.4.16.6. Market Size and Forecast, By Procurement Channel

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Market Size and Forecast, By Device Type
10.4.17.3. Market Size and Forecast, By Disease Indication
10.4.17.4. Market Size and Forecast, By End User
10.4.17.5. Market Size and Forecast, By Technology Type
10.4.17.6. Market Size and Forecast, By Procurement Channel

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Market Size and Forecast, By Device Type
10.4.18.3. Market Size and Forecast, By Disease Indication
10.4.18.4. Market Size and Forecast, By End User
10.4.18.5. Market Size and Forecast, By Technology Type
10.4.18.6. Market Size and Forecast, By Procurement Channel

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Market Size and Forecast, By Device Type
10.4.19.3. Market Size and Forecast, By Disease Indication
10.4.19.4. Market Size and Forecast, By End User
10.4.19.5. Market Size and Forecast, By Technology Type
10.4.19.6. Market Size and Forecast, By Procurement Channel

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Market Size and Forecast, By Device Type
10.4.20.3. Market Size and Forecast, By Disease Indication
10.4.20.4. Market Size and Forecast, By End User
10.4.20.5. Market Size and Forecast, By Technology Type
10.4.20.6. Market Size and Forecast, By Procurement Channel

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Market Size and Forecast, By Device Type
10.4.21.3. Market Size and Forecast, By Disease Indication
10.4.21.4. Market Size and Forecast, By End User
10.4.21.5. Market Size and Forecast, By Technology Type
10.4.21.6. Market Size and Forecast, By Procurement Channel

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Market Size and Forecast, By Device Type
10.4.22.3. Market Size and Forecast, By Disease Indication
10.4.22.4. Market Size and Forecast, By End User
10.4.22.5. Market Size and Forecast, By Technology Type
10.4.22.6. Market Size and Forecast, By Procurement Channel

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. Market Size and Forecast, By Device Type
10.4.23.3. Market Size and Forecast, By Disease Indication
10.4.23.4. Market Size and Forecast, By End User
10.4.23.5. Market Size and Forecast, By Technology Type
10.4.23.6. Market Size and Forecast, By Procurement Channel

10.4.24. Delaware

10.4.24.1. Overview
10.4.24.2. Market Size and Forecast, By Device Type
10.4.24.3. Market Size and Forecast, By Disease Indication
10.4.24.4. Market Size and Forecast, By End User
10.4.24.5. Market Size and Forecast, By Technology Type
10.4.24.6. Market Size and Forecast, By Procurement Channel

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers and Retinal Diagnostic Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035
10.5.4. Midwest Region Market Size and Forecast, By Device Type, 2021–2035
10.5.5. Midwest Region Market Size and Forecast, By Disease Indication, 2021–2035
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Market Size and Forecast, By Device Type
10.5.9.3. Market Size and Forecast, By Disease Indication
10.5.9.4. Market Size and Forecast, By End User
10.5.9.5. Market Size and Forecast, By Technology Type
10.5.9.6. Market Size and Forecast, By Procurement Channel

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Market Size and Forecast, By Device Type
10.5.10.3. Market Size and Forecast, By Disease Indication
10.5.10.4. Market Size and Forecast, By End User
10.5.10.5. Market Size and Forecast, By Technology Type
10.5.10.6. Market Size and Forecast, By Procurement Channel

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Market Size and Forecast, By Device Type
10.5.11.3. Market Size and Forecast, By Disease Indication
10.5.11.4. Market Size and Forecast, By End User
10.5.11.5. Market Size and Forecast, By Technology Type
10.5.11.6. Market Size and Forecast, By Procurement Channel

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Market Size and Forecast, By Device Type
10.5.12.3. Market Size and Forecast, By Disease Indication
10.5.12.4. Market Size and Forecast, By End User
10.5.12.5. Market Size and Forecast, By Technology Type
10.5.12.6. Market Size and Forecast, By Procurement Channel

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Market Size and Forecast, By Device Type
10.5.13.3. Market Size and Forecast, By Disease Indication
10.5.13.4. Market Size and Forecast, By End User
10.5.13.5. Market Size and Forecast, By Technology Type
10.5.13.6. Market Size and Forecast, By Procurement Channel

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Market Size and Forecast, By Device Type
10.5.14.3. Market Size and Forecast, By Disease Indication
10.5.14.4. Market Size and Forecast, By End User
10.5.14.5. Market Size and Forecast, By Technology Type
10.5.14.6. Market Size and Forecast, By Procurement Channel

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Market Size and Forecast, By Device Type
10.5.15.3. Market Size and Forecast, By Disease Indication
10.5.15.4. Market Size and Forecast, By End User
10.5.15.5. Market Size and Forecast, By Technology Type
10.5.15.6. Market Size and Forecast, By Procurement Channel

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Market Size and Forecast, By Device Type
10.5.16.3. Market Size and Forecast, By Disease Indication
10.5.16.4. Market Size and Forecast, By End User
10.5.16.5. Market Size and Forecast, By Technology Type
10.5.16.6. Market Size and Forecast, By Procurement Channel

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Market Size and Forecast, By Device Type
10.5.17.3. Market Size and Forecast, By Disease Indication
10.5.17.4. Market Size and Forecast, By End User
10.5.17.5. Market Size and Forecast, By Technology Type
10.5.17.6. Market Size and Forecast, By Procurement Channel

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Market Size and Forecast, By Device Type
10.5.18.3. Market Size and Forecast, By Disease Indication
10.5.18.4. Market Size and Forecast, By End User
10.5.18.5. Market Size and Forecast, By Technology Type
10.5.18.6. Market Size and Forecast, By Procurement Channel

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. Market Size and Forecast, By Device Type
10.5.19.3. Market Size and Forecast, By Disease Indication
10.5.19.4. Market Size and Forecast, By End User
10.5.19.5. Market Size and Forecast, By Technology Type
10.5.19.6. Market Size and Forecast, By Procurement Channel

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. Market Size and Forecast, By Device Type
10.5.20.3. Market Size and Forecast, By Disease Indication
10.5.20.4. Market Size and Forecast, By End User
10.5.20.5. Market Size and Forecast, By Technology Type
10.5.20.6. Market Size and Forecast, By Procurement Channel

What this section provides: This section delivers detailed four-region and all-50-state analysis, enabling clients to identify retinal disease burden hotspots, ophthalmology infrastructure clusters, technology-adoption centers, underserved screening opportunities and priority commercial territories.

11. U.S. Retinal Disease Diagnostic Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Product Portfolio Benchmarking
11.5. OCT and Multimodal Imaging Competitive Analysis
11.6. AI Retinal Diagnostics Competitive Analysis
11.7. U.S. Installed Base and Commercial Reach Analysis
11.8. Strategic Partnerships, M&A and Distribution Analysis

11.9. Company Profiles

11.9.1. Carl Zeiss Meditec AG
11.9.2. Topcon Healthcare
11.9.3. Heidelberg Engineering GmbH
11.9.4. Optos plc / Nikon Corporation
11.9.5. NIDEK Co., Ltd.
11.9.6. Canon Inc.
11.9.7. Kowa Company, Ltd.
11.9.8. Visionix / Optovue
11.9.9. iCare / CenterVue
11.9.10. Optomed Plc
11.9.11. Remidio Innovative Solutions
11.9.12. Phoenix Technology Group
11.9.13. Intalight
11.9.14. Tomey Corporation
11.9.15. Huvitz Co., Ltd.
11.9.16. Digital Diagnostics Inc.
11.9.17. Eyenuk, Inc.
11.9.18. AEYE Health Inc.
11.9.19. iHealthScreen, Inc.
11.9.20. Notal Vision, Inc.
11.9.21. RetinAI Medical AG
11.9.22. LumiThera / MacuLogix
11.9.23. Diagnosys LLC
11.9.24. Baxter / Welch Allyn
11.9.25. HEINE Optotechnik

Note: Each company profile will include company overview, retinal diagnostic product portfolio, U.S. market strategy, financial and commercial positioning, regulatory status, technology roadmap, partnerships, acquisitions and recent developments.

What this section provides: This section provides competitor benchmarking, market-share visibility, retinal imaging portfolio positioning, AI diagnostic capabilities, innovation direction and strategic intelligence on major established and emerging companies.

12. U.S. Retinal Disease Diagnostic Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis

12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario

12.2. Disruptive Technologies Impact

12.2.1. Swept-Source OCT
12.2.2. OCT Angiography and Multimodal Imaging
12.2.3. Autonomous AI-Based Retinal Screening
12.2.4. Ultra-Widefield and Portable Retinal Imaging
12.2.5. Home OCT and Remote Retinal Monitoring
12.2.6. AI-Based Longitudinal Disease Progression Analytics
12.2.7. Cloud-Native Ophthalmic Image Management

12.3. Future of Retina Diagnostic Workflow Automation
12.4. Emerging Business Models
12.5. Equipment-as-a-Service and Subscription Models
12.6. Business Opportunities for Startups and Existing Players
12.7. Investment Prioritization Matrix
12.8. High-Growth Device Opportunity Matrix
12.9. Disease Indication Opportunity Matrix
12.10. State-Level Expansion Opportunity Matrix

What this section provides: This section prepares clients for technology disruption, changing diagnostic workflows, new business models, investment opportunities and alternative market-development scenarios through 2035.

13. U.S. Retinal Disease Diagnostic Devices Market: Strategic Recommendations

13.1. Recommendations for Retinal Diagnostic Device Manufacturers
13.2. Recommendations for OCT and Imaging Platform Companies
13.3. Recommendations for AI Retinal Diagnostic Developers
13.4. Recommendations for Hospitals and Academic Eye Centers
13.5. Recommendations for Retina Specialty Practices
13.6. Recommendations for Ophthalmology and Optometry Groups
13.7. Recommendations for Diabetes and Primary-Care Screening Networks
13.8. Recommendations for Investors and Private Equity Firms
13.9. Recommendations for Distributors and Channel Partners
13.10. Recommendations for New Entrants and Startups
13.11. U.S. Go-to-Market Strategy Considerations
13.12. Product Positioning and Portfolio Expansion Guidance
13.13. State-Level Commercial Prioritization Strategy
13.14. Pricing and Contracting Strategy
13.15. AI and Digital Platform Partnership Strategy

What this section provides: This section converts market intelligence into actionable recommendations for product development, commercial expansion, capital allocation, market entry, channel strategy and competitive differentiation.

14. U.S. Retinal Disease Diagnostic Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Market Definition Limitation
14.3. Data Use Limitation
14.4. Forecasting Limitation
14.5. State-Level Estimate Limitation
14.6. Regulatory Information Limitation
14.7. Legal Disclaimer
14.8. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s analytical boundaries, data-use limitations, regulatory considerations, forecasting assumptions and legal conditions.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Retinal Disease Diagnostic Devices Market: Market Definition and Scope
TABLE 3: U.S. Retinal Disease Diagnostic Devices Market: Research Methodology Framework
TABLE 4: U.S. Retinal Disease Diagnostic Devices Market: Key Assumptions
TABLE 5: U.S. Retinal Disease Diagnostic Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Retinal Disease Diagnostic Devices Market: Stakeholder Analysis
TABLE 7: U.S. Retinal Disease Diagnostic Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Retinal Disease Diagnostic Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Retinal Disease Diagnostic Devices Market: Market Attractiveness Index
TABLE 10: U.S. Retinal Disease Diagnostic Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Retinal Disease Diagnostic Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Retinal Disease Diagnostic Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Retinal Disease Diagnostic Devices Market: Drivers & Impact Analysis
TABLE 14: U.S. Retinal Disease Diagnostic Devices Market: Restraints & Impact Analysis
TABLE 15: U.S. Retinal Disease Diagnostic Devices Market: Opportunities & Impact Analysis
TABLE 16: U.S. Retinal Disease Diagnostic Devices Market: Challenges & Impact Analysis
TABLE 17: U.S. Retinal Disease Diagnostic Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. Retinal Disease Diagnostic Devices Market: Retinal Imaging Clinical Workflow Economics Matrix
TABLE 19: U.S. Retinal Disease Diagnostic Devices Market: Ophthalmology Capital Procurement Behavior Matrix
TABLE 20: U.S. Retinal Disease Diagnostic Devices Market: Equipment Replacement Cycle Analysis
TABLE 21: U.S. Retinal Disease Diagnostic Devices Market: PESTEL Analysis
TABLE 22: U.S. Retinal Disease Diagnostic Devices Market: Porter’s Five Forces Analysis
TABLE 23: U.S. Retinal Disease Diagnostic Devices Market: Pricing Trend Analysis, 2025–2035
TABLE 24: U.S. Retinal Disease Diagnostic Devices Market: Value Chain Analysis
TABLE 25: U.S. Retinal Disease Diagnostic Devices Market: Supply Chain Analysis
TABLE 26: U.S. Retinal Disease Diagnostic Devices Market: Digitalization and Connected Ophthalmology Impact
TABLE 27: U.S. Retinal Disease Diagnostic Devices Market: Retinal Imaging Innovation Landscape
TABLE 28: U.S. Retinal Disease Diagnostic Devices Market: AI Retinal Diagnostics Landscape
TABLE 29: U.S. Retinal Disease Diagnostic Devices Market: FDA Regulatory Framework Analysis
TABLE 30: U.S. Retinal Disease Diagnostic Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 31: U.S. Retinal Disease Diagnostic Devices Market: Retinal Imaging Coding and Payment Environment
TABLE 32: U.S. Retinal Disease Diagnostic Devices Market: Import/Export and Tariff Impact
TABLE 33: U.S. Retinal Disease Diagnostic Devices Market: Vision-Screening and Public Health Initiatives
TABLE 34: U.S. Retinal Disease Diagnostic Devices Market: Device Type Snapshot, 2025
TABLE 35: Segment Dashboard; Definition and Scope, by Device Type
TABLE 36: U.S. Retinal Disease Diagnostic Devices Market, by Device Type, 2021–2035 (US$ Billion)
TABLE 37: U.S. Retinal Disease Diagnostic Devices Market: Segment Share Analysis, by Device Type, 2025 & 2035 (%)
TABLE 38: Optical Coherence Tomography Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 39: Fundus Imaging Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 40: Ultra-Widefield Retinal Imaging Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 41: Scanning Laser & Multimodal Retinal Imaging Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: Ophthalmic Ultrasound Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: AI-Enabled and Remote Retinal Diagnostic Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: Other Retinal Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Retinal Disease Diagnostic Devices Market: Disease Indication Snapshot, 2025
TABLE 46: Segment Dashboard; Definition and Scope, by Disease Indication
TABLE 47: U.S. Retinal Disease Diagnostic Devices Market, by Disease Indication, 2021–2035 (US$ Billion)
TABLE 48: U.S. Retinal Disease Diagnostic Devices Market: Segment Share Analysis, by Disease Indication, 2025 & 2035 (%)
TABLE 49: Age-Related Macular Degeneration Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: Diabetic Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: Retinal Vascular Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: Retinal Detachment & Vitreoretinal Disorder Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Inherited and Other Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Retinal Disease Diagnostic Devices Market: End User Snapshot, 2025
TABLE 55: Segment Dashboard; Definition and Scope, by End User
TABLE 56: U.S. Retinal Disease Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 57: U.S. Retinal Disease Diagnostic Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 58: Hospitals and Academic Eye Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: Retina Specialty Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: Comprehensive Ophthalmology & Optometry Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: Diabetes, Endocrinology & Primary-Care Screening Sites Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: Teleophthalmology & Remote Monitoring Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Retinal Disease Diagnostic Devices Market: Technology Type Snapshot, 2025
TABLE 64: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 65: U.S. Retinal Disease Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 66: U.S. Retinal Disease Diagnostic Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 67: Spectral-Domain OCT Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: Swept-Source OCT Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: OCT Angiography Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: Fundus Photography, Autofluorescence & Ultra-Widefield Imaging Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: AI-Enabled, Tele-Retina & Connected Imaging Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Retinal Disease Diagnostic Devices Market: Procurement Channel Snapshot, 2025
TABLE 73: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 74: U.S. Retinal Disease Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 75: U.S. Retinal Disease Diagnostic Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 76: Direct Manufacturer Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: Health System and Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: Distributor & Specialty Ophthalmic Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: Software, Subscription & Remote Diagnostic Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. Retinal Disease Diagnostic Devices Market: Regional Snapshot, 2025
TABLE 82: Segment Dashboard; Definition and Scope, by Geography
TABLE 83: U.S. Retinal Disease Diagnostic Devices Market, by Geography, 2021–2035 (US$ Billion)
TABLE 84: U.S. Retinal Disease Diagnostic Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 85: U.S. Retinal Disease Diagnostic Devices Market: Regional Retinal Disease Burden Analysis
TABLE 86: U.S. Retinal Disease Diagnostic Devices Market: Regional Ophthalmology and Retina Specialist Infrastructure
TABLE 87: U.S. Retinal Disease Diagnostic Devices Market: Regional Technology Adoption Index
TABLE 88: West Region U.S. Retinal Disease Diagnostic Devices Market: Regional Overview and Trends
TABLE 89: West Region U.S. Retinal Disease Diagnostic Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 90: West Region U.S. Retinal Disease Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 91: West Region U.S. Retinal Disease Diagnostic Devices Market, by Device Type, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Retinal Disease Diagnostic Devices Market, by Disease Indication, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Retinal Disease Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Retinal Disease Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. Retinal Disease Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 96: California Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Washington Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Arizona Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Colorado Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Oregon Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Utah Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Nevada Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: New Mexico Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Idaho Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Montana Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Wyoming Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Alaska Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Hawaii Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Northeast Region U.S. Retinal Disease Diagnostic Devices Market: Regional Overview and Trends
TABLE 110: Northeast Region U.S. Retinal Disease Diagnostic Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 111: Northeast Region U.S. Retinal Disease Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. Retinal Disease Diagnostic Devices Market, by Device Type, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. Retinal Disease Diagnostic Devices Market, by Disease Indication, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. Retinal Disease Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Retinal Disease Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 116: Northeast Region U.S. Retinal Disease Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 117: New York Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Massachusetts Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: New Jersey Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Pennsylvania Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Connecticut Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Maine Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Vermont Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: New Hampshire Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Rhode Island Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. Retinal Disease Diagnostic Devices Market: Regional Overview and Trends
TABLE 127: South Region U.S. Retinal Disease Diagnostic Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 128: South Region U.S. Retinal Disease Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 129: South Region U.S. Retinal Disease Diagnostic Devices Market, by Device Type, 2021–2035 (US$ Billion)
TABLE 130: South Region U.S. Retinal Disease Diagnostic Devices Market, by Disease Indication, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. Retinal Disease Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. Retinal Disease Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 133: South Region U.S. Retinal Disease Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 134: Texas Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Florida Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Georgia Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: North Carolina Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Tennessee Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: South Carolina Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Alabama Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Mississippi Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Louisiana Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Arkansas Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Kentucky Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Oklahoma Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Virginia Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Maryland Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: West Virginia Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Delaware Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Midwest Region U.S. Retinal Disease Diagnostic Devices Market: Regional Overview and Trends
TABLE 151: Midwest Region U.S. Retinal Disease Diagnostic Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 152: Midwest Region U.S. Retinal Disease Diagnostic Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 153: Midwest Region U.S. Retinal Disease Diagnostic Devices Market, by Device Type, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. Retinal Disease Diagnostic Devices Market, by Disease Indication, 2021–2035 (US$ Billion)
TABLE 155: Midwest Region U.S. Retinal Disease Diagnostic Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 156: Midwest Region U.S. Retinal Disease Diagnostic Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 157: Midwest Region U.S. Retinal Disease Diagnostic Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 158: Illinois Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Ohio Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Michigan Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Minnesota Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Indiana Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Wisconsin Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Missouri Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: Iowa Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Kansas Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Nebraska Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: North Dakota Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: South Dakota Retinal Disease Diagnostic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 170: U.S. Retinal Disease Diagnostic Devices Market: Competitive Landscape Snapshot, 2025
TABLE 171: U.S. Retinal Disease Diagnostic Devices Market: Key Company Market Share Analysis, 2025
TABLE 172: U.S. Retinal Disease Diagnostic Devices Market: Company Positioning Matrix
TABLE 173: U.S. Retinal Disease Diagnostic Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 174: U.S. Retinal Disease Diagnostic Devices Market: OCT and Multimodal Imaging Competitive Benchmark
TABLE 175: U.S. Retinal Disease Diagnostic Devices Market: AI Retinal Diagnostics Competitive Benchmark
TABLE 176: U.S. Retinal Disease Diagnostic Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 177: Carl Zeiss Meditec AG: Company Profile
TABLE 178: Topcon Healthcare: Company Profile
TABLE 179: Heidelberg Engineering GmbH: Company Profile
TABLE 180: Optos plc / Nikon Corporation: Company Profile
TABLE 181: NIDEK Co., Ltd.: Company Profile
TABLE 182: Canon Inc.: Company Profile
TABLE 183: Kowa Company, Ltd.: Company Profile
TABLE 184: Visionix / Optovue: Company Profile
TABLE 185: iCare / CenterVue: Company Profile
TABLE 186: Optomed Plc: Company Profile
TABLE 187: Remidio Innovative Solutions: Company Profile
TABLE 188: Phoenix Technology Group: Company Profile
TABLE 189: Intalight: Company Profile
TABLE 190: Tomey Corporation: Company Profile
TABLE 191: Huvitz Co., Ltd.: Company Profile
TABLE 192: Digital Diagnostics Inc.: Company Profile
TABLE 193: Eyenuk, Inc.: Company Profile
TABLE 194: AEYE Health Inc.: Company Profile
TABLE 195: iHealthScreen, Inc.: Company Profile
TABLE 196: Notal Vision, Inc.: Company Profile
TABLE 197: RetinAI Medical AG: Company Profile
TABLE 198: LumiThera / MacuLogix: Company Profile
TABLE 199: Diagnosys LLC: Company Profile
TABLE 200: Baxter / Welch Allyn: Company Profile
TABLE 201: HEINE Optotechnik: Company Profile
TABLE 202: U.S. Retinal Disease Diagnostic Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 203: U.S. Retinal Disease Diagnostic Devices Market: Disruptive Technologies Impact Matrix
TABLE 204: U.S. Retinal Disease Diagnostic Devices Market: Retina Diagnostic Workflow Automation Outlook
TABLE 205: U.S. Retinal Disease Diagnostic Devices Market: Emerging Business Models
TABLE 206: U.S. Retinal Disease Diagnostic Devices Market: Business Opportunities for Startups and Existing Players
TABLE 207: U.S. Retinal Disease Diagnostic Devices Market: Investment Prioritization Matrix
TABLE 208: U.S. Retinal Disease Diagnostic Devices Market: High-Growth Device Opportunity Matrix
TABLE 209: U.S. Retinal Disease Diagnostic Devices Market: Disease Indication Opportunity Matrix
TABLE 210: U.S. Retinal Disease Diagnostic Devices Market: State-Level Expansion Opportunity Matrix
TABLE 211: U.S. Retinal Disease Diagnostic Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 212: U.S. Retinal Disease Diagnostic Devices Market: Strategic Recommendations for OCT and Imaging Companies
TABLE 213: U.S. Retinal Disease Diagnostic Devices Market: Strategic Recommendations for AI Diagnostic Developers
TABLE 214: U.S. Retinal Disease Diagnostic Devices Market: Strategic Recommendations for Hospitals and Eye Centers
TABLE 215: U.S. Retinal Disease Diagnostic Devices Market: Strategic Recommendations for Retina Specialty Practices
TABLE 216: U.S. Retinal Disease Diagnostic Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 217: U.S. Retinal Disease Diagnostic Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 218: U.S. Retinal Disease Diagnostic Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 219: U.S. Retinal Disease Diagnostic Devices Market: Go-to-Market Strategy Considerations
TABLE 220: U.S. Retinal Disease Diagnostic Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 221: U.S. Retinal Disease Diagnostic Devices Market: Pricing and Contracting Strategy
TABLE 222: U.S. Retinal Disease Diagnostic Devices Market: Scope Limitation
TABLE 223: U.S. Retinal Disease Diagnostic Devices Market: Market Definition Limitation
TABLE 224: U.S. Retinal Disease Diagnostic Devices Market: Data Use Limitation
TABLE 225: U.S. Retinal Disease Diagnostic Devices Market: Forecasting Limitation
TABLE 226: U.S. Retinal Disease Diagnostic Devices Market: State-Level Estimate Limitation
TABLE 227: U.S. Retinal Disease Diagnostic Devices Market: Regulatory Information Limitation
TABLE 228: U.S. Retinal Disease Diagnostic Devices Market: Legal Disclaimer
TABLE 229: U.S. Retinal Disease Diagnostic Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Retinal Disease Diagnostic Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem Framework
FIGURE 4: Stakeholder Ecosystem
FIGURE 5: U.S. Retinal Disease Diagnostic Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. Retinal Disease Diagnostic Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. Retinal Disease Diagnostic Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 8: Market Attractiveness Analysis
FIGURE 9: Market Dynamics
FIGURE 10: Drivers and Restraints Impact Matrix
FIGURE 11: Innovation & Patent Landscape, 2021–2025
FIGURE 12: Retinal Imaging Clinical Workflow Economics Framework
FIGURE 13: Ophthalmology Capital Procurement Decision Framework
FIGURE 14: Retina Diagnostic Equipment Replacement Cycle
FIGURE 15: PESTEL Analysis
FIGURE 16: Porter’s Five Forces Analysis
FIGURE 17: Value Chain Analysis
FIGURE 18: Supply Chain Analysis
FIGURE 19: AI Retinal Diagnostics Ecosystem
FIGURE 20: FDA Regulatory Pathway Framework
FIGURE 21: CMS Reimbursement and Retinal Imaging Payment Framework
FIGURE 22: Device Type Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Device Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Optical Coherence Tomography Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 25: Fundus Imaging Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 26: Ultra-Widefield Retinal Imaging Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 27: AI-Enabled and Remote Retinal Diagnostic Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 28: Disease Indication Segment Market Share Analysis, 2025 & 2035
FIGURE 29: Disease Indication Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 30: Age-Related Macular Degeneration Diagnostic Devices Market Growth Trend, 2021–2035
FIGURE 31: Diabetic Retinal Disease Diagnostic Devices Market Growth Trend, 2021–2035
FIGURE 32: Retinal Vascular Disease Diagnostic Devices Market Growth Trend, 2021–2035
FIGURE 33: Retinal Detachment & Vitreoretinal Disorder Diagnostic Devices Market Growth Trend, 2021–2035
FIGURE 34: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 35: End User Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 36: Retina Specialty Clinics Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 37: Diabetes, Endocrinology & Primary-Care Screening Sites Market Growth Trend, 2021–2035
FIGURE 38: Teleophthalmology & Remote Monitoring Providers Market Growth Trend, 2021–2035
FIGURE 39: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 40: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 41: Spectral-Domain OCT Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 42: Swept-Source OCT Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 43: OCT Angiography Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 44: AI-Enabled, Tele-Retina & Connected Imaging Market Growth Trend, 2021–2035
FIGURE 45: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 46: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 47: Direct Manufacturer Sales Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 48: Software, Subscription & Remote Diagnostic Procurement Growth Trend, 2021–2035
FIGURE 49: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 50: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Regional Retinal Disease Burden and Technology Adoption Map
FIGURE 52: West Region Market Share Analysis by State, 2025
FIGURE 53: West Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 54: California Retinal Disease Diagnostic Devices Market Size and Trend Analysis, 2021–2035
FIGURE 55: West Region Retinal Diagnostic Technology Adoption Index
FIGURE 56: Northeast Region Market Share Analysis by State, 2025
FIGURE 57: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 58: New York Retinal Disease Diagnostic Devices Market Size and Trend Analysis, 2021–2035
FIGURE 59: Northeast Region Academic and Retina Specialist Infrastructure Map
FIGURE 60: South Region Market Share Analysis by State, 2025
FIGURE 61: South Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 62: Texas Retinal Disease Diagnostic Devices Market Size and Trend Analysis, 2021–2035
FIGURE 63: Florida Retinal Disease Diagnostic Devices Market Size and Trend Analysis, 2021–2035
FIGURE 64: South Region Diabetic Retinopathy and AMD Diagnostic Opportunity Map
FIGURE 65: Midwest Region Market Share Analysis by State, 2025
FIGURE 66: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 67: Illinois Retinal Disease Diagnostic Devices Market Size and Trend Analysis, 2021–2035
FIGURE 68: Midwest Region Tele-Retina and Rural Access Opportunity Map
FIGURE 69: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 70: Company Positioning Matrix
FIGURE 71: Key Player Product Portfolio Benchmarking
FIGURE 72: OCT and Multimodal Imaging Competitive Landscape
FIGURE 73: AI Retinal Diagnostics Competitive Landscape
FIGURE 74: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 75: U.S. Retinal Diagnostic Device Innovation Roadmap
FIGURE 76: Swept-Source OCT Adoption Roadmap
FIGURE 77: OCT Angiography Opportunity Roadmap
FIGURE 78: Autonomous AI Retinal Screening Adoption Roadmap
FIGURE 79: Home OCT and Remote Retinal Monitoring Growth Roadmap
FIGURE 80: Future Market Scenario Analysis, 2026–2035
FIGURE 81: Disruptive Technologies Impact Matrix
FIGURE 82: Emerging Business Models Matrix
FIGURE 83: High-Growth Device Opportunity Matrix
FIGURE 84: Disease Indication Opportunity Matrix
FIGURE 85: State-Level Commercial Expansion Opportunity Matrix
FIGURE 86: Investment Prioritization Matrix
FIGURE 87: Strategic Growth Roadmap for Retinal Diagnostic Device Manufacturers
FIGURE 88: U.S. Go-to-Market Strategy Framework
FIGURE 89: Product Positioning and Portfolio Expansion Framework
FIGURE 90: Pricing and Contracting Strategy Framework
FIGURE 91: AI and Digital Platform Partnership Framework
FIGURE 92: Report Scope and Disclaimer Framework